Evaluation demonstrates that ONT sequencing provides reliable methylation profiling and CNV analysis in medulloblastomas, suggesting enhanced classification.
Oxford Nanopore Technologies (ONT) enables rapid, onplatform DNA methylation profiling, but validation on FFPE material remains limited. We evaluated ONT sequencing for molecular classification and copynumber profiling in twelve FFPE medulloblastomas. Using nanoDx, subtype calls showed substantial concordance with Illumina Infinium MethylationEPIC v2.0/DKFZ references; Sturgeon provided moderate agreement. CNV profiles derived from ONT recapitulated EPIC v2.0 alterations, including events involving MYC, TP53, and CDK6. Our results demonstrate technical feasibility and analytical robustness of ONT in archival tissue, supporting its use as a rapid, costefficient complement to arraybased workflows. This proofofconcept supports broader adoption and prospective validation in clinical neurooncology practice.
No takes yet. Share an insight, caveat, or question.
Ficorilli et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: